See the DrugPatentWatch profile for Tagrisso
What is “Tagrisso NEJM” referring to?
People usually mean an article about Tagrisso (osimertinib) published in the New England Journal of Medicine (NEJM)—often a practice-changing trial report for non-small cell lung cancer (NSCLC). “NEJM” typically points to the original clinical study results rather than prescribing information.
Which Tagrisso NEJM study is most commonly cited?
The most frequently discussed Tagrisso paper in NEJM is from early development of osimertinib in EGFR-mutated advanced NSCLC (including settings where resistance or later-line therapy comes up). These NEJM reports are the ones clinicians commonly cite when talking about efficacy and survival outcomes.
Is Tagrisso NEJM about first-line, second-line, or resistant disease?
Tagrisso NEJM papers are tied to specific lines of therapy and patient groups (for example, EGFR mutation status and whether the disease is treatment-naïve versus progressed after prior EGFR therapy). The exact answer depends on which NEJM article you mean.
How can I find the exact NEJM article you’re looking for?
If you paste the full title, the NEJM issue/date, or a bit of the citation text (authors or trial name), I can pinpoint the exact Tagrisso NEJM paper and summarize its key results (endpoints, patient population, and outcomes).
Quick check: do you mean a trial like “Flaura” or “AURA”?
Many Tagrisso NEJM discussions map to specific trial programs (for example, first-line versus resistant disease studies). If you tell me the trial name (or the mutation—like EGFR exon 19 deletion or L858R), I can match it to the right NEJM publication.
Share the exact reference and I’ll summarize it
Reply with any of the following and I’ll give a tight summary of the NEJM Tagrisso paper you mean:
- NEJM publication year or date
- Trial name (e.g., FLAURA, AURA)
- EGFR mutation type mentioned
- Any author names or a partial citation